Tina Fawcett
Acute Care · Flagstaff, AZNPI 1326422700
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 190 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 14.5% — the pattern of someone who eats at a lot of different presentations.
Across 190 payments — averaging $20.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Grifols USA, LLC$575
- GSK$546
- Philips North America LLC$458
- AstraZeneca$429
- Takeda Pharmaceuticals U.S.A., Inc.$266
- Boehringer Ingelheim$261
- plus $1K from 16 others
What the payments were for
- Food & beverage$3,87898%
- Education$792%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Grifols USA, LLC | 28 | $575 |
| GSK | 29 | $546 |
| Philips North America LLC | 33 | $458 |
| AstraZeneca | 17 | $429 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $266 |
| Boehringer Ingelheim | 13 | $261 |
| Sanofi | 13 | $252 |
| Actelion Pharmaceuticals US, Inc. | 2 | $144 |
| Baxter Healthcare | 7 | $141 |
| Mylan Specialty L.p. | 6 | $129 |
| Regeneron Healthcare Solutions, Inc. | 5 | $117 |
| Convatec Inc. | 1 | $97 |
| Amgen | 4 | $92 |
| Insmed, Inc. | 4 | $84 |
| Viatris Specialty LLC | 4 | $84 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Verona Pharma, Inc. | 2 | $59 |
| Electromed, Inc. | 4 | $59 |
| Johnson & Johnson | 1 | $29 |
| Pulmonx Corporation | 1 | $19 |
| Gilead | 1 | $19 |
| Merck | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,957 in reported general payments places this provider in the 85th percentile of 482 acute care providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 440 | $621,710 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 251 | $281,134 |
| Spiriva RespimatTiotropium Bromide | 58 | $84,064 |
| Breo ElliptaFluticasone/Vilanterol | 91 | $81,201 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 86 | $78,961 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 59 | $59,775 |
| Incruse ElliptaUmeclidinium Bromide | 59 | $44,124 |
| Spiriva HandihalerTiotropium Bromide | 35 | $38,419 |
| SymbicortBudesonide/Formoterol Fumarate | 77 | $35,190 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 84 | $21,536 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 487 | $19,255 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 23 | $16,968 |
| Advair HfaFluticasone Propion/Salmeterol | 28 | $16,450 |
| Atrovent HfaIpratropium Bromide | 16 | $15,271 |
| Arnuity ElliptaFluticasone Furoate | 22 | $13,991 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $546 | $839,987698 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $429 | $328,758345 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $261 | $160,807140 claims |
| MerckDulera | $18 | $13,23016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 482 acute care providers in Arizona.
Other acute care in Flagstaff
- Nicole CiffoneTucson$162K
- Kim KrmpoticPhoenix$79K
- Stephanie WilsonScottsdale$37K
- Laura Cook-GongoraPhoenix$32K
- Cathy PaynePhoenix$26K
- Chandra SorrellePhoenix$16K
- Nicole RauscherPhoenix$12K
- Seania BristolMesa$11K
- Brooke GambinoPhoenix$11K
- Stephanie TironeGlendale$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.